Stock A170900 DONG-A ST CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Dong-A ST Co., Ltd.

Equities

A170900

KR7170900005

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
68,800 KRW -0.58% Intraday chart for Dong-A ST Co., Ltd. +2.84% -0.43%
Mar. 18 Dong-A ST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 24 GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd. CI

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company appears to be poorly valued given its net asset value.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

  • The company is not the most generous with respect to shareholders' compensation.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DONG-A ST CO., LTD. Stock Dong-A ST Co., Ltd.
-0.43% 437M -
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.05% 9.18B
A-
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.33% 4.78B
A-
YUHAN CORPORATION Stock Yuhan Corporation
+6.40% 3.87B
B-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+26.98% 3.73B -
INDIVIOR PLC Stock Indivior PLC
+28.27% 2.52B
B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.55% 2.27B -
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-25.02% 2.21B
C-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+5.82% 1.95B - -
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A170900 Stock
  4. Ratings Dong-A ST Co., Ltd.